Patient assessments and prescribing blood-thinning medications helps reduce incidence of deep vein thrombosis among U-M patients
The University of Michigan Health System has earned the DVTeamCare Hospital Award for its commitment to preventing potentially fatal blood clots.
The North American Thrombosis Forum (NATF), in coordination with Eisai Inc., selected the U-M Health System and the University of Mexico as the two university hospitals nationwide with more than 200 beds to receive the patient safety award.
Using patient assessments and medications, fewer U-M patients developed venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), blood clots that form in one or more of the deep veins, usually in the legs or pelvis, and can travel to the lungs.
“Many national efforts and organizations are looking at this complication and only focusing on certain patient populations,” says chief physician assistant Marc J. Moote, M.S., P.A.-C.,chairman of the U-M Venous Thromboembolism Prevention Committee.
“Our strategy is broader, focusing on all patients and evaluating each one individually. We’ve gone from performing zero formalized VTE risk assessments to more than 90 percent of hospitalized patients receiving a risk assessment, most within 24 hours of admission,” he says.
The U-M’s multidisciplinary strategy uses a risk assessment and computer-based order entry system to help providers calculate each patient’s VTE risk and recommend proper treatment based on their risk factors, such as a personal or family history of blood clots, or a recent surgery.
As a result, more than 90 percent of admitted patients received completed risk assessments within 24 hours and U-M prescribers tripled the number of at-risk patients receiving blood-thinning medications known to prevent VTE formation.
The cost-effective treatment option can reduce the odds of developing DVT by as much as 50 to 65 percent.
Each year, more than 1 million Americans will develop DVT or PE and nearly one-third of people will die.
NATF and Eisai Inc., a top U.S. pharmaceutical company, invited health care professionals nationwide to nominate their hospital for the DVTeamCare Hospital Award and share their protocols and implementation strategies for preventing DVT.
“We reviewed a series of submissions focused on venous thromboembolism prevention,” says John Fanikos, R.Ph., M.B.A., NATF treasurer, assistant director of pharmacy at the Brigham and Women’s Hospital and a member of the award judging committee.
“Every hospital went at the VTE epidemic full speed, using the resources they had available, and using their ingenuity in coming up with innovative ways to improve prophylaxis and reduce event rates.”
U-M will join other award recipients April 29 at NAFT’s Hospital DVT Prophylaxis Strategies Symposium in Boston, Mass., to present its innovative approach to VTE prevention.
In addition, awardees will be recognized among their peers and presented with a commemorative plaque during the NATF Annual Thrombosis Prevention Forum on April 28.
North American Thrombosis Forum